库尔库明@Fe/酸复杂纳米颗粒用于炎症性肠病治疗
Jiman Jin1, Xiuzhi Ye1, Zhenfeng Huang1
1The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou 325200, China.
ACS omega
|April 1, 2024
概括
一种使用黄素 (Cur) 封装在金属聚网络中的新型纳米药物输送系统通过减少炎症和改善肠道健康,有效治疗炎症性肠病 (IBD).
科学领域:
- 生物材料科学 生物材料科学
- 纳米医学是一种纳米医学.
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD) 由于其慢性和无法治愈的性质,构成了重大的公共卫生挑战.
- 现有的IBD治疗方法通常具有有限的疗效和不良副作用,突出显示出需要新的治疗策略.
- 黄素 (Cur) 是一种天然化合物,由于其抗炎和抗氧化特性,它对IBD治疗具有有前途的作用,但由于溶解性和生物可用性差,其治疗应用受到限制.
研究的目的:
- 为黄素 (Cur) 开发一种先进的纳米药物输送系统,以提高其在治疗炎症性肠病 (IBD) 中的疗效.
- 调查金属多网络作为纳米封装Cur的载体的潜力.
- 在IBD模型中评估新型纳米药物输送系统的稳定性,药物释放,生物相容性和治疗效果.
主要方法:
- 使用Fe3+/酸 (TA) 金属多网络制造Curcumin@Fe&TA (Cur@Fe&TA) 纳米药物输送系统,以封装纳米.
- 对Cur@Fe&TA纳米药物的稳定性,药物释放动力学和生物相容性进行表征.
- 在炎症性肠病 (IBD) 的小鼠模型中评估Cur@Fe&TA的治疗疗效,评估胃肠细胞病理,抗氧化剂水平和炎症性细胞因子调节.
主要成果:
- 该Cur@Fe&TA纳米药物输送系统表现出良好的稳定性,受控的药物释放行为和出色的生物相容性.
- 在IBD小鼠模型中,用Cur@Fe&TA治疗显著改善了胃肠道细胞病理.
- 纳米药物有效调节了抗氧化剂和炎症性细胞因子的水平,表明它具有强大的抗炎作用.
结论:
- 开发的Cur@Fe&TA纳米药物代表了治疗炎症性肠病 (IBD) 的有希望和创新的方法.
- 金属聚网络提供了一个可行的策略,用于封装和提供治疗剂,如黄素,克服可溶性和生物利用性的局限性.
- 这种纳米药物输送系统通过其结合的抗氧化和抗炎作用,为未来的临床应用在治疗IBD方面具有显著的潜力.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127